search for




 

The Effects of Subtenon Triamcinolone Injection in Patients with Idiopathic Epiretinal Membrane after Vitrectomy
Ann Optom Contact Lens 2019;18:15-22
Published online March 25, 2019
© 2019 The Korean Optometry & Contact Lens Study Society

Joo Young Kim, MD1, Mirinae Kim, MD1, Young Hoon Park, MD, PhD1,2

Department of Ophthalmology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea1, Seoul, Korea, Catholic Institute for Visual Science, College of Medicine, The Catholic University of Korea2, Seoul, Korea
Correspondence to: Young Hoon Park, MD, PhD
Department of Ophthalmology and Visual Science, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, #222 Banpo-daero, Seocho-gu, Seoul 06591, Korea, Tel: 82-2-2258-6201, Fax: 82-2-599-7405, E-mail: parkyh@catholic.ac.kr
Received February 1, 2019; Revised March 12, 2019; Accepted March 16, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Purpose: To evaluate the effects of subtenon triamcinolone injections in patients with macular edema or low visual improvement after undergoing vitrectomy for treatment of idiopathic epiretinal membrane.
Methods: We conducted a retrospective chart review of 45 eyes of 45 patients who were diagnosed with idiopathic epiretinal membrane and underwent vitrectomy, but did not have more than 0.1 logarithm of the minimum angle of resolution (logMAR) increase in best corrected visual acuity (BCVA) after the operation. Of the 45 patients, 24 patients received 40 mg triamcinolone injection in subtenon space in 2 to 5 months after the operation, and 21 patients received no injection. We analyzed BCVA, central macular thickness (CMT), intraocular pressure (IOP), and complications in 1, 2, 6, and 12 months after the operation.
Results: Before the operation, the mean BCVA and CMT in the injection group were 0.53 ± 0.16 and 616.58 ± 143.44 μm, and those in the non-injection group were 0.51 ± 0.25 and 566.29 ± 116.33 μm, respectively. 12 months after the operation, the mean BCVA and CMT in the injection group improved to 0.24 ± 0.17 and 373.11 ± 80.91 μm and those in the non-injection group were 0.28 ± 0.26 and 354.75 ± 80.03 μm, respectively. The difference between the two groups was not statistically significant. At 6 months postoperatively, the IOP was significantly higher in the injection group than that in the non-injection group.
Conclusions: Patients with idiopathic epiretinal membrane did not show further improvement in BCVA and CMT when they received the subtenon triamcinolone injection after vitrectomy.
Keywords : Epiretinal membrane; Macular edema; Subtenon triamcinolone; Vitrectomy


June 2019, 18 (2)